RSV Vaccination Produces 60% Antibody Response in Immunocompromised Persons

A recent study published by the JAMA Network measured antibody response to Respiratory syncytial virus (RSV) vaccinations in immunocompromised individuals.

This Research Letter, published on December 30, 2024, disclosed a heterogeneous antibody response to RSV vaccines among immunocompromised persons.

In contrast to universal seroconversion and preF IgG fold rises greater than 10 in immunocompetent persons, approximately 40% of immunocompromised participants did not seroconvert or achieve a conservative neutralization threshold postvaccination.

Better neutralization was seen among RSVA-AS01E (AREXVY™) recipients, suggesting possible augmentation by the vaccine adjuvant.

These researchers wrote, 'Low antibody titers may indicate a role for additional vaccine doses to enhance immune response among immunocompromised persons.

As of December 31, 2024, various RSV vaccines are offered at local pharmacies, and monoclonal antibody passive immunization is approved.